Holen Sie sich die Stockscreener-App
1.115
0.44%
-0.01
Schlusskurs vom Vortag:
$1.125
Offen:
$1.13
24-Stunden-Volumen:
308.85K
Relative Volume:
0.22
Marktkapitalisierung:
$139.44M
Einnahmen:
$1.78M
Nettoeinkommen (Verlust:
$-68.36M
KGV:
-1.633
EPS:
-0.6828
Netto-Cashflow:
$-51.59M
1W Leistung:
-5.08%
1M Leistung:
-8.20%
6M Leistung:
-32.93%
1J Leistung:
-34.88%
1-Tages-Spanne:
$1.11
$1.14
1-Wochen-Bereich:
$1.11
$1.26
52-Wochen-Spanne:
$1.00
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Firmenname
Milestone Pharmaceuticals Inc
Sektor
Branche
Telefon
(514) 336-0444
Adresse
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.12 | 140.06M | 1.78M | -68.36M | -51.59M | -0.6828 |
VRTX
Vertex Pharmaceuticals Inc
|
522.23 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.44 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-15 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-09-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-06-20 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-03 | Eingeleitet | Cowen | Outperform |
| 2019-06-03 | Eingeleitet | Jefferies | Buy |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
Milestone Pharmaceuticals at Wells Fargo: launch gains, bigger test ahead By Investing.com - Investing.com Canada
Milestone Pharma's nasal spray gets first ex-US approval - The Pharma Letter
Milestone Pharmaceuticals Inc. (MIST) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
MIST Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Milestone Pharmaceuticals (MIST) Gains China Approval for Etripa - GuruFocus
Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co - TradingView
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States - Yahoo Finance
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress - Yahoo Finance
Milestone Pharmaceuticals Inc. (MIST) Key Financial Ratios – Valuation, Profitability & More - Value Research
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences - The Manila Times
Three investor events are set for Boston and New York, with Milestone joining - Stock Titan
Milestone Pharmaceuticals stock holds at $1.16 as fundamentals and outlook stay in focus - AD HOC NEWS
Milestone Pharmaceuticals Inc. (MIST) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Milestone presents study on PSVT impact between episodes By Investing.com - Investing.com Canada
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes - GlobeNewswire
Milestone presents study on PSVT impact between episodes - Investing.com
First Patient Enrolled in the Phase 3 ReVeRA-301 Pivotal Trial for Afib - dicardiology.com
Milestone (MIST) Earnings Snapshot: Reported EPS Misses Expectations for the Current Session; Stock Move: Shares Finish 1.90% Lower in the Current UpdateEarnings Recovery Stocks - vinanet.vn
Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation - Yahoo
Milestone (MIST) Results Breakdown: EPS Comes in Below Forecast in Latest Trading; Latest Reaction: The Stock Records a 2.43% Increase for the Current SessionFree Cash Flow Trends - vinanet.vn
Milestone Pharmaceuticals (NASDAQ:MIST) Advances Trial Path - Kalkine Media
Milestone Pharmaceuticals begins phase 3 trial for AFib treatment By Investing.com - Investing.com Nigeria
Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial - Yahoo Finance
Milestone Pharmaceuticals (MIST) Launches Phase 3 Trial Amidst High Price-to-Sales Valuation - GuruFocus
Milestone Pharmaceuticals stock gains on Phase 3 AFib trial By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals stock gains on Phase 3 AFib trial - Investing.com
Milestone Pharmaceuticals begins phase 3 trial for AFib treatment - Investing.com
Milestone Pharmaceuticals Enrolls First Patient in Phase 3 ReVeRA-301 Trial of Etripamil for AFib-RVR - Quiver Quantitative
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) - The Manila Times
This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Cantor Fitzgerald initiates Milestone Pharmaceuticals stock coverage with overweight rating - Investing.com Canada
MIST Initiated Coverage by Cantor Fitzgerald -- Rating Overweight - GuruFocus
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound (NASDAQ:MIST) - Seeking Alpha
Milestone Pharmaceuticals (MIST) Climbs 2.8% as Shares Hold Above $1.04 SupportShort Setup Alerts - vinanet.vn
Milestone’s FDA Win Now Faces A Tougher Test: Sales - Finimize
What is HC Wainwright's Forecast for MIST Q3 Earnings? - MarketBeat
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Earnings To Watch: Milestone Scientific Inc (MLSS) Q2 2026 -- GF Value Sees 13% Upside - finance.yahoo.com
What is HC Wainwright's Estimate for MIST FY2028 Earnings? - MarketBeat
Wells Fargo Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Milestone Pharmaceuticals earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Milestone Pharmaceuticals Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Releases Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Milestone Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Milestone Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Milestone Pharmaceuticals Q2 Results: Net loss widens to $28.6M - scanx.trade
Milestone Pharmaceuticals Inc (MIST) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Milestone posts Q2 loss as CARDAMYST launch gains traction - Investing.com
Q2 2026 Milestone Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Form 8K MILESTONE PHARMACEUTICALS INC. For: 12 August By Investing.com - Investing.com South Africa
Finanzdaten der Milestone Pharmaceuticals Inc-Aktie (MIST)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):